Результаты поиска

Calcium-Permeable Channels Cooperation for Rheumatoid Arthritis: Therapeutic Opportunities.

Rheumatoid arthritis is a common autoimmune disease that results from the deposition of antibodies-autoantigens in the joints, leading to long-lasting inflammation. The main features of RA include cartilage damage, synovial invasion and flare-ups of intra-articular inflammation, and these pathological processes significantly reduce patients' quality of life. To date, there is still no drug target that can act in rheumatoid arthritis. Therefore, the search for novel drug targets has become urgent. Due to their unique physicochemical properties, calcium ions play an important role in all cellula

Совпадение в полном тексте источника
… The data showed that TRPV5 −/− mice still underwent significant bone resorption and that treatment with alendronate normalized bone thickness in these mice [ 126 ]. … Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice J. Bone Miner. Res. 2008 23 1815 1824 10.1359/jbmr.080613 18597625 127. Chamoux E. Bisson M. Payet M.D. Roux S. …

Early-Onset Osteoporosis: Rare Monogenic Forms Elucidate the Complexity of Disease Pathogenesis Beyond Type I Collagen.

Early-onset osteoporosis (EOOP), characterized by low bone mineral density (BMD) and fractures, affects children, premenopausal women and men aged <50 years. EOOP may be secondary to a chronic illness, long-term medication, nutritional deficiencies, etc. If no such cause is identified, EOOP is regarded primary and may then be related to rare variants in genes playing a pivotal role in bone homeostasis. If the cause remains unknown, EOOP is considered idiopathic. The scope of this review is to guide through clinical and genetic diagnostics of EOOP, summarize the present knowledge on rare monoge

Совпадение в полном тексте источника
… After the initial diagnosis of osteoporosis based on DXA scanning, she was treated with alendronate until the age of 42 years. Her family history was positive for osteoporosis and fractures, prompting genetic studies for OI. … In general, the use of bisphosphonates, such as pamidronate, alendronate, and zoledronate, to reduce osteoclast activity, increases BMD in patients with OI whereas its effect on fractures is less certain. ( 188 , 189 ) Clinical studies concerning denosumab, a monoclonal antibody inhibiting osteoclast …

Всемирный конгресс по болезням остеопороза, остеоартрита и мускулоскелета 2025).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… For non-vertebral fracture, abaloparatide was better than any other treatment while teriparatide was only superior to alendronate or placebo. PTH1 analogs were better than placebo at reducing all fractures while no difference was observed for the risk of hip fracture. …

Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.

The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some of these chronic pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased tissue degradation, and some exhibit a combination of both, leading to severe tissue alterations. To develop effective therapies for diseases affecting the lung, liver, kidney, skin, intestine, musculoskeletal system, heart, and solid tumors, we need to modulate the ECM's composition to restore its organization and function. Across diverse organ diseases, there are common denom

Совпадение в полном тексте источника
… Data from one study [ 64 ] showed that CTX-I can predict bone mass changes in osteoporosis patients treated with alendronate as early as three months, while changes were not detectable on X-ray until 12 months [ 65 ]. …

Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions.

Bone metastases occur in 65-75% of patients with metastatic breast cancer. They are often associated with skeletal-related events (SREs), leading to significant morbidity and decline in quality of life (QoL). Treatment with bone-modifying agents is crucial to decrease the risk of SREs and improve QoL. We used PubMed to review key clinical trials that studied the use of bisphosphonates (BPs) and denosumab for the treatment of osseous metastases in patients with metastatic breast cancer. We also reviewed agents that may have the potential to improve SREs. BPs - including clodronate, pamidronate,

Совпадение в полном тексте источника
… The increase in bone density was greater with romosozumab compared to alendronate or teriparatide. The largest gains were observed with a 210-mg monthly dose, given subcutaneously every month for 12 months. The increase in bone formation markers was transient. …

Potential Role of Oral Microbiota in Medication-Related Osteonecrosis of the Jaw in Cancer Patients: A Narrative Review.

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication frequently observed in cancer patients undergoing antiresorptive therapies, such as bisphosphonates and denosumab. Emerging evidence suggests that dysbiosis of the oral microbiota plays a pivotal role in the pathogenesis of MRONJ. The complex interplay between microbial communities, host immune responses, and the effects of cancer treatments creates an environment conducive to pathogenic colonization, chronic inflammation, and impaired bone healing, which are the key hallmarks of MRONJ. Chemotherapy, radiotherapy, and

Совпадение в полном тексте источника
… Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Evans KD, Oberbauer AM. Open Orthop J. 2009;3:83–88. doi: 10.2174/1874325000903010083. 16. The role of the immune response in the development of medication-related osteonecrosis of the jaw. …

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients.

Objective Myeloma-related bone disease (MBD) is one of the most common complications of multiple myeloma (MM). This study aims to investigate the correlation between serum bone metabolism indexes (BMIs), the clinical characteristics and prognosis of newly diagnosed MM (NDMM) patients.MethodsThe serum BMIs of 148 patients with NDMM in a single hematological disease treatment center from April 2014 to December 2019 were analyzed retrospectively, including type I collagen amino terminal elongation peptide (PINP), β-C-terminal telopeptide of type I collagen (β-CTX) and N-terminal osteocalcin (N-MI

Совпадение в полном тексте источника
… All patients received bisphosphate therapy according to the diagnostic and treatment guidelines, and intravenous zoledronic acid injection or oral alendronate sodium were chosen based on the patient’s renal function. Table 1. Clinical characteristics of 148 MM patients. …

Oral Graft-Versus-Host Disease: A Pictorial Review and a Guide for Dental Practitioners.

IntroductionGraft-versus-host disease (GVHD) is a complication of haematopoietic stem cell transplantation (HSCT). GVHD may also develop following solid transplants or blood transfusions if white blood cells are transferred. GVHD affects multiple organs, including the oral tissues.ObjectiveThis pictorial review provides a background of GVHD to dental practitioners, describes the most common oral manifestations of GVHD and highlights the main treatment modifications needed to deliver dental care to patients with GVHD.MethodsA narrative review enhanced with clinical photographs.ResultsAcute GVHD

Совпадение в полном тексте источника
… The long-term use of high-dose steroids results in osteoporosis, which is treated with alendronate, a risk factor for osteonecrosis of the jaw. Additionally, some multiple myeloma patients undergo allogeneic HSCT. …

EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage.

BackgroundNew drugs are generally claimed to represent a therapeutic innovation. However, scientific evidence of a substantial clinical advantage is often lacking. This may be the result of using inadequate control groups or surrogate outcomes only in the clinical trials. In view of this, EVITA was developed as a user-friendly transparent tool for the early evaluation of the additional therapeutic value of a new drug.MethodsEVITA does not evaluate a new compound per se but in an approved indication in comparison with existing therapeutic strategies. Placebo as a comparator is accepted only in

Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross‑sectional study.

BACKGROUND: Bisphosphonates are widely prescribed for osteoporosis, Paget's disease, and malignancy-related bone disease. While effective in reducing skeletal complications, they are associated with medication-related osteonecrosis of the jaw (MRONJ), a serious but preventable condition. Medical practitioners play a central role in initiating therapy, educating patients, and coordinating referrals, yet data on awareness and practices in Malaysia remain limited. OBJECTIVE: This study assessed the awareness, prescribing practices, and perceived roles of medical practitioners at a university hos

Совпадение в полном тексте источника
… These findings are consistent with prescribing trends reported in Saudi Arabia, where both alendronate and denosumab were among the most frequently used antiresorptive agents [ 11 ]. …

Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an updated review on the etiology, pathogenesis, clinical presentation, and management of malignancy-related hypercalcemia. We searched PubMed/Medline, Scopus, Embase, and Web of Science for original articles, case reports, and case series articles focused on hypercalcemia of malignancy published from 1950 to December 2014. Hypercalcemia of malignancy usually presents with markedly elevated calcium levels and therefore, usually severely symptomatic. Several major mechani

Совпадение в полном тексте источника
… The first-generation or nonnitrogen-containing bisphosphonates include etidronate and clodronate, which are less commonly used nowadays.[ 54 55 ] The second-generation or nitrogen-containing bisphosphonates include such medications as alendronate, risedronate, ibandronate, pamidronate, and zoledronic …

An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment.

Cancer is recognized as one of the world's deadliest diseases, with more than 10 million new cases each year. Over the past 2 decades, several studies have been performed on cancer to pursue solutions for effective treatment. One of the vital benefits of utilizing nanoparticles (NPs) in cancer treatment is their high adaptability for modification and amalgamation of different physicochemical properties to boost their anti-cancer activity. Various nanomaterials have been designed as nanocarriers attributing nontoxic and biocompatible drug delivery systems with improved bioactivity. The present

Совпадение в полном тексте источника
… Abbreviations: ES-SSL-PTX, Estrogen sterically stabilized long-acting paclitaxel; PLAD-MLP, Pegylated liposome co-encapsulated Alendronate and Doxorubicin-Mitomycin-C lipidic prodrug; PLGA-PEG-GEM+BA, Polylactide-co-glycolide- polyethylene glycol-gemcitabine+betulinic acid; PAMAM, Polyamidoamine; GALD … ES-SSL-PTX) | 135.93 nm | Estrogen-receptive sterically stabilized long-acting paclitaxel liposome | Breast cancer | Paclitaxel | 37 2. | Liposomal (PLAD-MLP) | 110 nm | Liposome formulation for several drugs with desirable pharmacological characteristics | Liver cancer & Lung cancer | Doxorubicin & Alendronate …

Long-term follow-up of vertebral compression fractures in inpatients treated with integrative Korean medicine: An observational study.

Conservative management is the recommended first-line treatment for thoracolumbar vertebral compression fractures (VCFs), with integrative Korean medicine (IKM) being widely used for treatment in Korea. However, evidence regarding long-term treatment outcomes is lacking. We aimed to investigate the effectiveness of IKM treatment for thoracolumbar VCFs. Data from inpatients with thoracolumbar VCFs who received IKM treatment, comprising acupuncture, pharmacopuncture, electroacupuncture, Chuna manual therapy, and herbal medicine, at 4 KM hospitals from April 1, 2016 to June 30, 2022 were analyzed

Совпадение в полном тексте источника
… Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. Bone. 1999;25:613–9. [29] Bo Ram KM, Lee I-S, Koh S-E, Kim S-W, Kim SB, Kim SY. …

Laser Devices and Autologous Platelet Concentrates in Prevention and Treatment of Medication-Related Osteonecrosis of the Jaws: A Systematic Review.

Background and Objectives: Medication-related osteonecrosis of the jaws (MRONJ) is a disease that affects many patients taking anti-angiogenic and antiresorptive medicines. Since the pathogenetic mechanism is still partially unknown, preventive strategies, as well as treatment alternatives, are needed. Therefore, the aim of this research is to describe the main evidence from the last 10 years of clinical trials regarding the use of auxiliary devices such as autologous platelet concentrates (APCs) and laser, other than their effects against MRONJ disease onset or therapy. Advantages in the heal

Совпадение в полном тексте источника
… Moreover, it has been demonstrated that PBMT inhibits keratinocytes apoptosis induced by alendronate, alongside other well-known effects such as cell migration, proliferation, and differentiation. …

Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series.

Medication-induced jaw osteonecrosis (MRONJ) is a rare and serious disease with a negative impact on patients' quality of life, whose exact cause remains unclear and which may have a multifactorial origin. Although there are different therapeutic protocols, there is still no consensus. This case series evaluated three patients diagnosed with staged 2 MRONJ treated at the University of Murcia dental clinic according to the protocols described by the Spanish Society of Oral and Maxillofacial Surgery and the American Association of Oral and Maxillofacial Surgeons. Within 12 months of the applicat

Совпадение в полном тексте источника
… Case 1: Conservative Treatment A 60-year-old woman smoker diagnosed with breast cancer, had received oral alendronate (Fosamax weekly, MSD, Madrid, Spain) for 10 months to combat osteoporosis caused by ovarian suppression, chemotherapy treatment, and the postmenopausal state itself. …

Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo.

Osteoporosis is characterized by a reduction of the bone mineral density (BMD) and microarchitectural deterioration of the bone, which lead to bone fragility and susceptibility to fracture. Astaxanthin (AST) has a variety of biological activities, such as a protective effect against asthma or neuroinflammation, antioxidant effect, and decrease of the osteoclast number in the right mandibles in the periodontitis model. Although treatment with AST is known to have an effect on inflammation, no studies on the effect of AST exposure on bone loss have been performed. Thus, in the present study, we

Совпадение в полном тексте источника
… Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cells in vitro. Exp. Ther. Med. 2017;14:1769–1774. doi: 10.3892/etm.2017.4695. 14. Ishimi Y., Miyaura C., Ohmura M., Onoe Y., Sato T., Uchiyama Y., Ito M., Wang X., Suda T., Ikegami S. …

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.

BackgroundBone-targeted agents such as bisphosphonates and the RANKL antibody have revolutionised the care of patients with bone metastases. There has, however been increasing concern about the oral health of these patients and in particular osteonecrosis of the jaw (ONJ), especially with the increasing use of these agents at higher potencies for greater periods of time.MethodsA review of the published data in PubMed and meeting abstracts was performed to examine incidence, risk factors, pathogenesis, clinical course and management of osteonecrosis of the jaw with focus on cancer patients trea

Совпадение в полном тексте источника
… Given the very long half-life of bisphosphonates in bone, with a 12-year terminal half-life even for oral agents like alendronate, effects of temporary cessation of the agents is questionable [31] , [46] . …

RANK, RANKL and osteoprotegerin in bone biology and disease.

Upon the discovery of RANK, RANKL and OPG in the late 1990s, their importance in the maintenance of the skeletal structure and their dramatic role in bone disease were largely unexpected. In recent years the understanding of these proteins, in particular their regulation, has greatly increased. This review aims to bring the interested reader up to date with the latest news and views on the mechanisms controlling bone resorption in normal and pathological conditions.

Совпадение в полном тексте источника
… Brown JP Prince RL Deal C Recker RR Kiel DP de Gregorio LH Hadji P Hofbauer LC Alvaro-Gracia JM Wang H Austin M Wagman RB Newmark R Libanati C San Martin J Bone HG Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal …

Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.

BackgroundA critical gap exits in understanding the dynamics of patient-based benefit-risk assessment (BRA) of medicines in chronic diseases during the disease journey.PurposeTo systematically review and synthesize current evidence on the changes of patients' preferences about the benefits and risks of medicines during their disease journey including the influence of disease duration and severity, and previous treatment experience.MethodsA systematic review of studies identified in PubMed and Embase, from inception to November 2020, was conducted in accordance with the PRISMA (Preferred Report

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials.

Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption. Denosumab inhibits bone loss; therefore, it is used to treat metabolic bone diseases (including postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis), in clinical practice. Since then, multiple effects of denosumab have been discovered. A growing body of evidence suggests that denosumab has a variety of pharmacological activities and broad pote

Совпадение в полном тексте источника
… Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: A randomized, controlled trial. J Bone mineral Res Off J Am Soc Bone Mineral Res (2019) 34(6):1014–24. doi: 10.1002/jbmr.3676 58. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. …